PDGFRB and gastrointestinal stromal tumor: Furthermore, ongoing preclinical trials are testing the therapeutic effect of another PDGFR inhibitor, imatinib mesylate, in gastrointestinal stromal tumor [40, 41] and in vitro and in vivo studies of malignant peripheral nerve sheath tumors have shown promising results [42].